HUMDF.PK

Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

Retrieved on: 
星期一, 十月 10, 2022

For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required.

Key Points: 
  • For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required.
  • Therefore, it is not only a major R&D breakthrough in translating innovative concepts into innovative products, but also a pioneering path for China in developing first-in-class drugs independently.
  • Going forward, Hua Medicine will partner with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.
  • This partnership aims at leveraging Bayer's prominent advantages in diabetes management in China and Hua Medicine's R&D expertise in diabetes treatment.

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Retrieved on: 
星期二, 六月 7, 2022
DREAM, Woman, National Medical Products Administration, GK, Company, FPG, GKA, Observation, DAWN, Research, Jak Airport, ADA, CEO, Education, Disease, World Diabetes Day, Type 2 diabetes, Insulin resistance, Patient, Glycated hemoglobin, Insulin, Metformin, Trial of the century, Chinese, Glucokinase, Type 2, Association, American Diabetes Association, Department, Public health, Hospital, NDA, Blood, Homeostasis, Drug development, Chinese University of Hong Kong, Attention, Glucose clamp technique, China-Japan Friendship Hospital, WIN, SEED, Pharmaceutical industry, Epidemiology, Diabetes, T2D

A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

Key Points: 
  • A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).
  • Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity.
  • The study results, using glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent onset T2D.
  • Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China.

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Retrieved on: 
星期五, 五月 13, 2022
Diabetes, JAMA, Nature Reviews Drug Discovery, Company, Glucose, National Medical Products Administration, BMJ, Blood, Journal, Drug discovery, American Diabetes Association, GSIS, Pancreas, Medical college, Patient, Hypoglycemia, Homeostasis, Phase, NEJM, DAWN, Liver, Medical journal, Nanjing University, GKA, The New England Journal of Medicine, Trial of the century, Research, FPG, ADA, GK, NMPA, Safety, Insulin, Glucagon, NDA, American Medical Association, The Lancet, Metformin, Glucokinase, Insulin resistance, SEED, Medical Center, Hong Kong Stock Exchange, Inborn errors of metabolism, Glycated hemoglobin, Nature Medicine, Pharmaceutical industry, Medical device, Endocrinology, T2D, Lancet

The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.

Key Points: 
  • The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept.
  • Before, the results of the Phase II clinical trial of dorzagliatin were published in the advanced medical journal The Lancet Diabetes and Endocrinology.
  • These two newly published papers present the Phase III results of the SEED study and the DAWN study of dorzagliatin, respectively.
  • Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs.